Drug Profile

PHT 776

Alternative Names: HBP 143; HPB-143; PHT-776

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Polymed Biopharmaceuticals
Class Anti-inflammatories; Small molecules
Mechanism of Action IRAK4 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Atopic dermatitis; Hidradenitis suppurativa

Most Recent Events

20 Feb 2025 Photys Therapeutics in-licenses PHT 776 from Hangzhou Polymed Biopharmaceuticals
20 Feb 2025 Preclinical trials in Atopic dermatitis in USA (PO)
20 Feb 2025 Preclinical trials in Hidradenitis suppurativa in USA (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com